Welcome to our dedicated page for Bio Rad Labs news (Ticker: BIO), a resource for investors and traders seeking the latest updates and insights on Bio Rad Labs stock.
Stay informed about Bio-Rad Laboratories (NYSE: BIO), a global manufacturer of life science research and clinical diagnostic products. Bio-Rad operates through two segments: Life Science, which provides instruments and reagents for protein purification, gene expression, and digital PCR applications; and Clinical Diagnostics, which offers products for diabetes monitoring, blood transfusion testing, and laboratory quality control.
The company serves customers worldwide including research institutions, hospitals, clinical laboratories, biotechnology companies, and pharmaceutical manufacturers. Bio-Rad's product portfolio includes Droplet Digital PCR systems for absolute quantification of nucleic acids, chromatography instruments for protein purification, electrophoresis and imaging systems, diabetes monitoring solutions utilizing HPLC technology, and comprehensive immunohematology products for blood typing and transfusion medicine.
Bio-Rad is recognized as the global market leader in clinical quality control products and systems that ensure the accuracy of laboratory test results. The company's technologies support applications across basic research, drug discovery and development, biopharmaceutical manufacturing, clinical diagnostics, food safety testing, and environmental monitoring. Track the latest developments in Bio-Rad's product innovations, regulatory approvals, strategic partnerships, and market expansion initiatives.
Bio-Rad Laboratories, Inc. will have its COO and CFO participate in a fireside chat during the RBC Capital Markets Global Healthcare Conference on May 14, 2024. The event will be webcasted and available for replay on the company's Investor Relations website.
FAQ
What is the current stock price of Bio Rad Labs (BIO)?
What is the market cap of Bio Rad Labs (BIO)?
